Cuprina Holdings (Cayman) LTD

Cuprina Holdings (Cayman) Limited held an Extraordinary General Meeting of Shareholders on October 15, 2026. Shareholders overwhelmingly approved three key proposals: a significant increase in the company's authorized share capital from US$100,000 to US$10,000,000, the adoption of new Amended and Restated Memorandum and Articles of Association to reflect this change and other updates, and the authorization for the chairman to adjourn the meeting if needed. The Class B shares carry 100 votes each, significantly influencing the voting outcomes.

Cuprina Holdings (Cayman) Limited filed an F-1 registration statement for a public offering of its Class A Ordinary Shares on Nasdaq. The Singapore-based biomedical and biotechnology company, which develops chronic wound care and cosmeceutical products, reported a net loss of US$3.63 million on revenue of US$38,789 for the year ended December 31, 2025. The company is an emerging growth company and a foreign private issuer, planning to use the proceeds for supply chain expansion, marketing, and working capital.

Cuprina Holdings announced that its subsidiary, Cuprina Pte. Ltd., received U.S. FDA 510(k) clearance for MEDIFLY Maggots, a medical-grade Lucilia cuprina larvae product for maggot debridement therapy. This marks the first U.S. clearance for a Lucilia cuprina maggot debridement product, expanding Cuprina's portfolio to include both major maggot species used in MDT. The product is cleared for debridement of non-healing necrotic skin and soft tissue wounds, and the company believes this clearance will accelerate regulatory pathways in other international markets.

Cuprina Holdings (Cayman) Limited announced it has regained compliance with the Nasdaq Capital Market's listing requirements, specifically the minimum bid price rule of $1.00 per share. The company had previously been notified of non-compliance and had appealed the decision. Nasdaq's Listing Qualifications staff have confirmed compliance, leading to the cancellation of a previously scheduled hearing and ensuring the continued listing of its shares on the Nasdaq Capital Market.

Cuprina Holdings announced it has regained compliance with the Nasdaq Capital Markets Listing Requirements, specifically the minimum bid price rule. The company had previously received a delisting determination letter and appealed the decision. As a result of regaining compliance, the hearing before the Nasdaq Hearing Panel, scheduled for July 7, 2026, has been cancelled, and the company's shares will continue to trade on Nasdaq.

Cuprina Holdings completed a reverse stock split on May 27, 2026, and requested a hearing with the Nasdaq Hearings Panel to appeal a delisting determination. The company received a notice on May 27, 2026, stating it failed to regain compliance with Nasdaq's $1.00 minimum bid price requirement by the May 26, 2026 deadline. The hearing request will stay the suspension of its securities, allowing them to continue trading on Nasdaq while the appeal is pending. Cuprina remains committed to maintaining its Nasdaq listing.

Cuprina Holdings announced a 1-for-8 share consolidation of its Class A and Class B ordinary shares, effective around May 27, 2026. This move aims to help the biomedical company regain compliance with Nasdaq listing requirements and maintain its presence on the Nasdaq Capital Market. Post-consolidation, shares will trade under the same symbol "CUPR" but with a new CUSIP number. The consolidation, approved by both the board and shareholders, will convert eight existing shares into one new share, with fractional shares rounded up.

Cuprina Holdings (Cayman) Limited shareholders approved all nine proposals at its 2026 Annual Meeting held on May 14, 2026. Key approvals include a 1-for-8 share consolidation for both Class A and Class B Ordinary Shares, an increase in Class B Ordinary Share voting rights from 10 to 100 votes per share, and an increase in authorized share capital from US$50,000 to US$100,000. Additionally, shareholders re-elected six directors, appointed J&S Associate PLT as auditors, and approved the 2026 Employee Incentive Plan and potential future share issuances.

Cuprina Holdings (Cayman) Limited filed a Form 6-K/A to amend its previous Form 6-K from April 21, 2026. The amendment specifically changes the voting deadline and the date of the annual general meeting. The AGM is now set to be held on May 14, 2026, with related proxy materials and an employee incentive plan included as exhibits.

Cuprina Holdings (Cayman) Limited filed a Form 6-K/A to amend its previously filed Form 6-K from April 21, 2026. The amendment specifically changes the voting deadline and the date of the Annual General Meeting, which is now scheduled for May 14, 2026. The filing includes exhibits such as the Notice of Annual General Meeting, Proxy Statement, Proxy Card, the 2026 Employee Incentive Plan, and the amended Articles of Association.